Navigation Links
China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent
Date:4/3/2008

BEIJING, April 3, 2008 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products and high intensity focused ultrasound tumor therapy systems, today announced the completion of development of the Prostate Cancer FISH Detection Kit (the "Kit"), a prostate cancer-specific molecular diagnostic test based on the Fluorescent in situ Hybridization ("FISH") technology. The Company expects to launch the Kit in July 2008.

The Kit is designed to detect TMPRSS2 and ETS gene fusions in prostate pathological tissues. Dysregulation of ETS family members through fusions with TMPRSS2 are implicated as cancer-causing gene rearrangements in prostate cancer, which can aid in the detection of early prostate cancer. The Kit consists of three dual-color probe sets, namely TMPRSS2/ETV1 probes, TMPRSS2/ERG probes and TMPRSS2/ETV4 probes. Studies have shown that TMPRSS2/ETS gene fusions occur in approximately 80 percent of prostate cancer cases, indicating that the application of TMPRSS2/ETS gene fusions as specific biomarkers can significantly increase the sensitivity for prostate cancer diagnosis. In addition, it has been reported that the TMPRSS2/ERG fusion may have prognostic significance.

"The successful development of the Kit is a milestone in expanding our FISH reagent portfolio, which represents the first significant product developed by our researchers since the FISH acquisition in 2007," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "Our FISH business has become an important growth driver of the Company and we believe the continual launch of new FISH reagents with huge potential of diagnostic application will drive the growth of our recurring reagent business rapidly."

Prostate cancer is one of the most frequent cancers among men in China and many other countries. In China, prostate-related diseases affect about 60-70% of men over 60 years of age of which the population is about 80 million. Among them, patients with prostate enlargement who need surgical therapy have the opportunity to benefit from the use of the Kit to resolve the diagnosis of prostate cancer.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

For more information, please contact:

China Medical Technologies, Inc.

Sam Tsang

Tel: +86-10-6530-8833

Email: IR@chinameditech.com


'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results
2. China Shenghuo Pharmaceutical Holdings, Inc. to Present at Brean Murray Carret & Co. Mainland China Investor Tour
3. China Nepstar Chain Drugstore to Accept TransCard at Shenzhen Outlets
4. China Bionanometer Industries (CBIU) Describes their Current Production Capacity and Product Lines
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. China Shenghuo Reports Full Year 2007 Financial Results
7. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
8. China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour
9. China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
10. China Yingxia International Announces Soybean Milk Production Lines Acquisition
11. Cells from the Research Institute of the MUHC on the road to China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact on ... Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... in order to thrive this year? , The passage of the act means devicemakers ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today that Dan Grover ... and marketing strategies. Grover comes with a total of 15 years experience in consumer ... as Executive Vice President of Direct Sales at Traeger® Wood Pellet Grills. , ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... age-related lines and wrinkles. Few people know that popular cosmetic fillers ... Richard Buckley, who is medical director of the MilfordMD Cosmetic Dermatology Surgery & ...
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China ... ... (PRWEB) January 18, 2017 -- Global public health ... to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking ... for drinking water treatment units. This certification verifies that MicroCeramics’ ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... Oregon and PUNE, India , January 18, 2017 ... Research, titled, "Polyphenol Market by Product Type and by Application: Global Opportunity Analysis ... $757 million in 2015, and is expected to reach $1,127 million by 2022, ... the market in 2015, with two-fifths share, in terms of revenue. ... ...
(Date:1/18/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The global CINV drugs market to grow at a ... Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. To ...
Breaking Medicine Technology: